Presentation on the topic "bronchial asthma in children". Bronchial asthma Bronchial asthma

BRONCHIAL ASTHMA is a disease that develops on the basis of chronic allergic inflammation of the bronchi, their hyperreactivity and is characterized by recurrent bouts of difficulty breathing or suffocation as a result of widespread bronchial obstruction caused by bronchoconstriction, mucus hypersecretion, swelling of the bronchial wall.

The prevalence of asthma in Russia is from 10 to 25% In Perm, at the end of 2010, more than 3,700 children were registered (growth in 2010 ≈ ≈ 4.1%) In Perm, 400-500 children are diagnosed with bronchial asthma for the first time every year 67% have bronchial asthma asthma manifests in the first 5 years of life (Balabolkin I.I., 2003)

New version of the National Program: “Bronchial asthma in children. Treatment strategy and prevention” 1992 recommendations of the international pediatric group on asthma 1997 on the initiative of the All-Russian Scientific Society of Pulmonologists of Russia developed the first National Program “Bronchial Asthma in Children” in 2005 (second edition) of the National Program “Bronchial Asthma in Children. Treatment strategy and prevention". 2008 . new version (third edition), revised and supplemented The goal of the program is to form a unified position in the fight against the most widespread lung disease in children. RUSSIAN RESPIRATORY SOCIETY UNION OF RUSSIAN PEDIATRICS NATIONAL PROGRAM “BRONCHIAL ASTHMA IN CHILDREN. TREATMENT STRATEGY AND PREVENTION ((THIRD EDITION)

Heredity The risk of asthma in a child of parents with signs of atopy is 2-3 times higher than in a child of parents who do not have it. Genetic factors determine the predisposition to allergic diseases. Allergic diseases are more often noted in the pedigree along the mother's side. The polygenic type of inheritance is considered predominant.

Atopy This is the body's ability to produce an increased amount of Ig. E in response to exposure to environmental allergens. It is detected in 80-90% of sick children.

Bronchial hyperreactivity This is a condition expressed in an increased reaction of the bronchi to an irritant, in which bronchial obstruction develops in response to exposure that does not cause such a reaction in most healthy individuals. This is a universal characteristic of bronchial asthma, its degree correlates with the severity of the disease. There is evidence of the genetic determinism of bronchial hyperreactivity

Etiological factors In children of 1 year of age - food and drug allergies. In children 1-3 years old - household, epidermal, fungal allergies. Older than 3-4 years - pollen sensitization. When living in contaminated industrial areas - sensitization to industrial substances. Recently, with bronchial asthma in children, the frequency of polyvalent sensitization has increased.

Causes of respiratory allergies Household allergens: : House dust mites of the Pyroglyphidae family: : DD ermatophagoides pteronissinus, farinae and microceras, Euroglyphus Animal allergens: : Cats, dogs, rodents, horses Fungal allergens: : Mold spores Aspergillus, Candida Pollen allergens Food allergens AD factors are: atmospheric pollutants (exhaust gases, ozone, nitrogen oxide, sulfur dioxide); indoors - tobacco smoke

Factors contributing to the occurrence of bronchial asthma are frequent respiratory infections, the pathological course of pregnancy in the mother of the child, prematurity, the presence of atopic dermatitis, indoor and outdoor air pollution, smoking, including passive smoking.

Factors causing exacerbation of bronchial asthma (triggers) contact with allergens, respiratory viral infection, physical activity, psycho-emotional stress, changes in the weather situation.

Mechanisms of development of bronchial asthma Under the influence of allergens in patients with BA there is hyperproduction of Ig. E B-lymphocytes There is an interaction of causally significant allergens with specific Ig fixed on mast cells and basophils.

This leads to the activation of target cells and the secretion of mediators and cytokines from them, which, in turn, contribute to the involvement of other fixed cells in the lungs and blood cells in the allergic process. Mediators such as histamine, prostaglandins, serotonin, etc. are released from the granules of mast cells. .

An acute allergic reaction develops, proceeding according to the immediate type and manifesting as a syndrome of bronchial obstruction. An asthma attack develops 10-20 minutes after contact with a causally significant allergen.

The late phase of an allergic reaction in the bronchi in response to allergen exposure develops after 6-8 hours and is characterized by an influx of pro-inflammatory cells into the lungs, followed by the development of allergic airway inflammation, hyperreactivity and bronchial obstruction.

Bronchial remodeling Massive death of epithelial cells A large number of mucous plugs Thickening of the basement membrane Hypertrophy and hyperplasia of goblet cells and serous glands Hypertrophy of smooth muscles (by 200%) Active angiogenesis

Classification of bronchial asthma Form (atopic, mixed) Stage of the disease (exacerbation with indication of the severity of the attack, remission) Severity of the disease (mild episodic and persistent, moderate, severe) Complications

frequency of attacks: mild intermittent - less than 1 time per month mild persistent - 1-3 times per month moderate - 1-2 times a week severe - 3 or more times a week

severity of attacks: mild asthma - only mild attacks moderate asthma - at least one attack of moderate severity severe asthma - at least one severe attack or history of status

The duration of the post-attack period with mild - 1-2 days moderate - 1 - 2 weeks severe - 2 - 4 weeks

duration of single-stage remission: mild asthma - more than 3 months moderate asthma - 1-3 months severe asthma - 1 month

the effectiveness of basic therapy: mild BA - symptoms are controlled, II — — III stage of basic therapy moderate BA — — IIIIII stage of basic therapy severe BA — — IVIV — — V V stage of basic therapy

CRITERIA FOR ASTHMATIC STATUS 1. 1. duration of non-stopping attack of bronchial asthma for at least 6 hours; 2. 2. violation of the drainage function of the bronchi; 3. 3. hypoxemia (partial pressure of oxygen less than 60 mm Hg) and hypercapnia (partial pressure of carbon dioxide more than 60 mm Hg); 4. 4. resistance to sympathomimetic drugs.

Stages of status asthmaticus Stage I - the stage of relative compensation - clinically represents a protracted asthma attack. It is characterized by severe violations of bronchial patency and resistance to sympathomimetics.

Rapid, difficult noisy breathing, increased emphysema, hard breathing and a significant amount of dry and sometimes wet rales. Delayed expectoration. Severe tachycardia, increased blood pressure. Signs of respiratory failure in the form of anxiety of the child, pallor of the skin, acrocyanosis.

The stage of increasing respiratory failure It develops as a result of total obstruction of the bronchial lumen with a thick viscous secret with the simultaneous presence of pronounced edema of the mucous membrane of the bronchial tree and spasm of the smooth muscles of the bronchi.

The weakening and subsequent disappearance of respiratory sounds are characteristic, first in separate segments of the lungs, then in its lobes, in the whole lung. The so-called "syndrome of silence in the lungs" is formed. Simultaneously with the weakening of breathing, diffuse cyanosis increases, tachycardia persists. BP goes down.

Hypoxic coma Deep respiratory failure with the presence of a syndrome of "silence" throughout the field of the lungs, adynamia, followed by loss of consciousness and convulsions. On examination, there is diffuse cyanosis of the skin and mucous membranes, the absence of respiratory sounds in the lungs, muscle and arterial hypotension, and a drop in cardiac activity.

Clinical diagnosis of bronchial asthma in children is based on the identification of symptoms such as: episodic expiratory dyspnea wheezing feeling of chest tightness paroxysmal cough

Clinical manifestations of bronchial asthma in young children An attack of shortness of breath and / or cough is manifested by a pronounced anxiety of the child (“rushing about”, “does not find a place for himself”) Chest swelling, fixation of the shoulder girdle in the inspiratory phase Tachypnea with a slight predominance of the expiratory component Violation of conduction breathing in the basal parts of the lungs Severe perioral cyanosis

During a physical examination in the lungs, against the background of uneven breathing, diffuse dry, wheezing rales are heard, as well as wet rales of various sizes. The presence of wet rales is especially characteristic of asthmatic attacks in young children (the so-called wet asthma). Symptoms of the disease, as a rule, appear or intensify at night. and in the morning hours

Anamnestic data Hereditary burden of allergic diseases The presence of concomitant diseases of allergic genesis in a sick child Indications of the dependence of the onset of symptoms of the disease on exposure to certain allergens Improvement after the use of bronchodilators

Laboratory and instrumental methods for diagnosing bronchial asthma 1. 1. Examination of blood smears (increase in the number of eosinophils more than 400 - 450 in 1 μl of blood) 2. 2. Determination of local eosinophilia (eosinophilia index is normally not more than 15 units) 3. 3. Definition cause-significant allergen by skin testing

Laboratory and instrumental methods for diagnosing bronchial asthma (continued) 4. Radioimmune, enzyme immunoassay, chemiluminescent methods for determining specific Ig. E and Ig. G-antibodies in the blood 5. Inhalation provocative tests with allergens 6. Chest X-ray (diffuse increase in the transparency of the lung tissue)

Laboratory and instrumental methods for diagnosing bronchial asthma (continued) 7. 7. Peak flowmetry (decrease in peak expiratory flow rate and forced expiratory volume in the first second) 8. 8. Spirography (impaired bronchial patency at the level of small bronchi and a positive test with bronchodilators) 9. 9. Detection in the bronchial secretion of a large number of eosinophils, as well as Kurschman spirals and Charcot-Leiden crystals

Laboratory and instrumental methods for diagnosing bronchial asthma (continued) 10. Immunological examination 11. Blood gas examination 12. Bronchoscopy 13. Determination of eosinophilic cationic protein 14. Determination of nitric oxide in exhaled air

Primary prevention of bronchial asthma in children elimination of occupational hazards in the mother during pregnancy; smoking cessation during pregnancy; rational nutrition of a pregnant, lactating woman with a restriction of products with high allergenic activity;

prevention of acute respiratory viral infections in the mother during pregnancy and in the child; limiting drug treatment during pregnancy by strict indications; breast-feeding; hypoallergenic environment of the child; cessation of passive smoking; the use of methods of physical rehabilitation, hardening of children; favorable ecological situation.

Hypoallergenic diet Exclusion of causally significant allergens Exclusion of histamine-liberator products (chocolate, citrus fruits, tomatoes, canned food, smoked meats, marinades, sauerkraut, fermented cheeses, etc.)

Pet allergens Get rid of pets if possible, do not get new ones Animals should never be in the bedroom Wash pets regularly

Elimination of pollen allergens Stay indoors more during flowering Close windows in the apartment, raise windows and use a protective filter in the car air conditioner while driving outside the city Try to leave your permanent place of residence for another climatic zone (for example, take a vacation) during the flowering season

Elimination of house dust allergens Use protective bed covers Replace down pillows and mattresses, as well as woolen blankets with synthetic ones, wash them every week at a temperature of 6000 C Get rid of carpets, thick curtains, soft toys (especially in the bedroom), do not wet clean less than once a week, and use washing vacuum cleaners with disposable bags and filters or vacuum cleaners with a water tank, pay special attention to cleaning furniture upholstered with fabrics.

Key Points Asthma can be effectively controlled in most patients, but there is no cure. The most effective treatment for asthma is to eliminate the causative allergen. Insufficient diagnosis and inadequate therapy are the main causes of severe asthma and mortality.

The choice of treatment should be made taking into account the severity of the course and the period of bronchial asthma. When prescribing drugs, a “graded” approach is recommended. In complex therapy, non-drug methods of treatment are often used. Successful treatment of asthma is impossible without the establishment of partnerships, trusting relationships between a doctor, a sick child, his parents and relatives.

Means of basic therapy Glucocorticosteroids Leukotriene receptor antagonists Prolonged β 22-agonists in combination with inhaled glucocorticosteroids Cromones (cromoglycic acid, nedocromil sodium) Prolonged theophyllines Antibodies to Ig.

Cromones Cromoglycate sodium (Intal) - 1-2 doses 4 times a day Nedocromil sodium (Tailed) 1-2 doses 2 times a day

IGCS in asthma Beclomethasone Budesonide Fluticasone Beclason Clenil-jet Tafennovolizer Pulmicort Flixotide

Average doses of ICS beclomethasone up to 600 mcg per day budesonide up to 400 mcg per day fluticasone up to 500 mcg per day

Antileukotriene drugs 1. 5-lipoxygenase- (leukotriene biosynthesis) inhibitors: zileuton (Zyflo) is used primarily in the USA 2. Cys. LT 1 antagonists: : montelukast (Singulair), zafirlukast (Accolate), pranlukast (Ono) So-called FLAP inhibitors, which prevent 5-LO activation of proteins, are being clinically studied (not yet in clinical practice). .

Pranlukast. Montelukast. Zafirlukast Recommended dose Chemical name Trade name Accolate Singulair Ono, Ultair 20-40 mg 2 times a day 1 hour before or 2 hours after meals Children over 12 years Children 6-14 years: 5 mg Children 2-5 years: 4 mg 1 once a day, at night, chewable tablet Adults: 225 mg twice a day not registered in Russia Leukotriene receptor antagonists used in clinical practice

Long-acting B22-adrenergic receptor agonists Salmeterol: Serevent Serevent rotadisk Salmeter Formoterol: Oxys Foradil Atimos

Antibodies to Ig. E (omalizumab - Xolair) The drug is: : humanized monoclonal antibodies obtained on the basis of recombinant DNA. Pharmacotherapeutic group: other agents for systemic use in obstructive airway diseases. Included in the international and Russian standards for the treatment of asthma as an additional therapy in the absence of control with the help of existing drugs

Verified diagnosis of moderate to severe atopic asthma (the atopic nature of the disease is confirmed by skin tests or radioallergosorbent test (RAST) Anti-Ig. E therapy is indicated for asthma, poorly or partially controlled by the use of basic therapy: - > 2 severe exacerbations per year, requiring the use of systemic GCS Frequent daytime symptoms (> 2 episodes per week) Nocturnal symptoms Significantly restricted lifestyle Age 12 years and older Ig.E levels ranging from 30 to 700 IU/mL

Relief of an attack of bronchial asthma inhalation of a β 22 agonist (salbutamol, berotek) or an anticholinergic (atrovent) or their combination (berodual) at an age dose using PAI (1 dose up to 10 years, 2 doses after 10 years) or through a nebulizer (berodual 1 drop per kg of weight) in the absence of effect after 20 minutes, repeat the drug in the same dose in the absence of effect from the second inhalation: call an ambulance,

Short-acting B22-adrenergic receptor agonists Salbutamol Salamol Eco Light breathing Ventolin (nebules) Salben Bricanil (Terbutaline) Fenoterol Berotek Hexoprenaline Ipradol Iprotropium bromide/fenoterol Berodual

1. 1. Administer prednisolone IM or IV 2 mg/kg or dexazone 0.3 mg/kg 2. 2. Administer eufillin 2, 4% solution, 8 mg/kg IV drip, 3. 3. if there is no effect within 1-2 hours of the above treatment, prednisone is repeated up to 10 mg/kg or dexazon 1 mg/kg for 6 hours, eufillin 1 mg/kg/hour IV drip (titration),

6. in case of moderate and severe attack, additionally O 22, 7. in case of status: β 22 - temporarily cancel agonists, glucocorticoids up to 30 mg / kg / day, bronchoscopy and lavage of the tracheobronchial tree, mechanical ventilation, correction of acid-base balance, water and electrolyte balance, titration of aminophylline before the status is terminated.

Step 1 Step 2 Step 3 Step 4 Step 5GINA 2006: Steps of Therapy Patient Education Environmental Control ββ 22 - fast acting agonist on demand ββ 22 - fast acting agonist on demand Disease control drug options Select one Add one or more Add one or more Both low-dose ICS ++ ββ 22 -long-acting IGCS in medium or high doses ++ ββ 22 -long-acting agonists Anti-leuko-triene drug IGCS in medium or high doses + Anti-leukotriye new drug + p / o GCS ( lowest dose)) Cromon IGCS in low doses plus antileukotriene drug + Theophylline MB + Anti-Ig. E-therapy Low-dose glucocorticosteroids plus theophylline MB Decrease increase

dose adjustment (every two months) In the absence of attacks - a permanent dose reduction If there are only mild attacks that are rarer than those characteristic of the severity of the disease - maintain the dose for the next two months If more frequent mild attacks or an attack of moderate, severe degree - the dose of the drug raise

Non-drug methods of treating bronchial asthma in children 1. 1. Diet therapy 2. 2. Respiratory therapy 3. 3. Relaxation and autogenic training 4. 4. Chest massage (vibration, percussion) 5. 5. Therapeutic exercise with breathing exercises

6. 6. Speleotherapy and halotherapy 7. 7. Physiotherapy 8. 8. Laser therapy 9. 9. Acupuncture 10. Phytotherapy 11. Psychotherapeutic correction of the neuropsychic status of the patient

slide 2

The concept of Bronchial asthma Asthma is a disease characterized by chronic inflammation of the airways, leading to hyperactivity in response to various stimuli and recurring attacks of bronchial obstruction.

slide 3

Clinic The main signs of bronchial asthma are asthma attacks. Asphyxiation attacks are divided into the following periods: Harbingers Attacks Post-attacks Interictals

slide 4

The period of precursors - comes a few minutes or a day before the attack. The period is characterized by: Anxiety Sneezing Itchy eyes Lachrymation Headache Sleep disturbance Dry cough

slide 5

The attack period is characterized by: Shortness of breath Wheezing Wheezing Pale skin Slight cyanosis Tachycardia, etc. During an attack, a person takes a sitting position and rests his hands on the edge of a bed or chair. The duration of the attack is 10-20 minutes, with a long course of up to several hours.

slide 6

Slide 7

Internal risk factors genetic predisposition; atopy (hyperproduction of IgE in response to the intake of an allergen); airway hyperreactivity; gender (more often in women); racial identity.

Slide 8

Slide 9

Factors that provoke exacerbation of BA: domestic and external allergens; indoor and outdoor pollutants; respiratory infections; physical activity and hyperventilation; changing weather conditions; sulfur dioxide; food, nutritional supplements, medicines; excessive emotional stress; smoking (passive and active); irritants (house spray, paint smell).

slide 10

Cells involved in the formation of the inflammatory process in AD: Primary effector cells: mast cells (histamine); macrophages (cytokines); epithelial cells. Secondary effector cells: eosinophils; T-lymphocytes; neutrophils; platelets.

slide 11

Forms of bronchial obstruction: acute bronchospasm, swelling of the bronchial wall (subacute), chronic obstruction with mucus, remodeling of the bronchial wall. Normal FEV1 (forced expiratory volume in the first second) - at least 75% of VC

slide 12

Degrees of pulmonary obstruction: more than 70% - mild; 69-50% - moderate; less than 50% - severe.

slide 13

CLASSIFICATION OF BA (according to ICD X): BA: atopic (exogenous); non-allergic (endogenous, aspirin); mixed (allergic + non-allergic); unspecified. Asthmatic status (acute severe asthma). Aspirin: PG deficiency is observed in AD, and aspirin (like other NSAIDs) further reduces their level. Salicylic acid is found in a variety of foods, so it's important not to confuse this form of asthma with a food allergy.

slide 14

ASTH SEVERITY CLASSIFICATION Stage 1: intermittent asthma symptoms less than once a week; short exacerbations; nocturnal symptoms no more than 2 times a month; FEV1 or PSV indicators are 80% or more of the proper values; PEF or FEV1 variability is less than 20%.

slide 15

Stage 3: persistent moderate asthma daily symptoms; exacerbations can affect physical activity and sleep; nighttime symptoms more than once a week; daily intake of inhaled B2-agonists; FEV1 or PSV indicators are 60-80% of the proper values; the variability in PSV or FEV1 is more than 30%.

slide 16

Stage 2: mild persistent asthma symptoms more than once a week, but less than once a day; exacerbations can affect physical activity and sleep; night symptoms more than 2 times a month; FEV1 or PSV indicators are 80% or more of the proper values; the variability in PSV or FEV1 is 20-30%.

slide 17

Stage 4: severe persistent asthma daily symptoms; frequent exacerbations; frequent nocturnal symptoms; limitation of physical activity; indicators of FEV1 or PSV are less than 60% of the proper values.

slide 18

TREATMENT OF BA Complex therapy of patients with BA 1. Education of patients. 2. Assessing and monitoring the severity of asthma. 3. Elimination of triggers or control of their influence on the course of the disease. 4. Development of a drug therapy plan for permanent treatment. 5. Development of a treatment plan during an exacerbation. 6. Ensuring regular supervision.

To use the preview of presentations, create a Google account (account) and sign in: https://accounts.google.com

Slides captions:

Bronchial asthma IN CHILDREN

Concept of Bronchial Asthma Asthma is a disease characterized by chronic inflammation of the airways, leading to hyperactivity in response to various stimuli and recurring bouts of bronchial obstruction.

Clinic The main signs of bronchial asthma are asthma attacks. Asphyxiation attacks are divided into the following periods: Harbingers Attacks Post-attacks Interictals

The period of precursors - comes a few minutes or a day before the attack. The period is characterized by: Anxiety Sneezing Itchy eyes Lachrymation Headache Sleep disturbance Dry cough

Risk factors

Internal risk factors genetic predisposition; atopy (hyperproduction of IgE in response to the intake of an allergen); airway hyperreactivity; gender (more often in women); racial identity.

Degrees of pulmonary obstruction: - more than 70% - mild; 69-50% - moderate; less than 50% - severe.

Drug therapy I. Asthma control drugs inhaled corticosteroids (beclomethasone dipropionate, budesonide, flunisomide, fluticasone, triamcinolone acetonide); systemic corticosteroids (prednisolone, methylprednisolone); (!) p / e: oral candidiasis, hoarseness, cough from irritation of the mucous membrane; sodium cromoglycate (intal); nedocromil sodium (Thyled); sustained release theophylline (teopec, teodur); long-acting inhaled β2-agonists (formoterol, salmeterol); antileukotriene drugs: a) cysteinyl-leukotriene 1 receptor antagonists (montelukast, zafirlukast), b) 5-lipoxygenase inhibitor (zileuton).

II. Symptomatic agents (for emergency care) inhaled fast-acting β2-agonists (salbutamol, fenoterol, terbutaline, reproterone); systemic GCS; anticholinergics (ipratropium bromide (Atrovent), oxitropium bromide); methylxanthines (theophylline IV, aminophylline).

III. Non-traditional treatments acupuncture; homeopathy; yoga; ionizers; speleotherapy; Buteyko method; etc.

Examination methods X-ray Examination of sputum Examination of blood

Thank you for your attention

slide 2

Bronchial asthma -

Chronic inflammatory disease of the airways involving mast cells, eosinophils, T-lymphocytes, mediators of allergy and inflammation, accompanied in predisposed individuals by hyperreactivity and variable (reversible) bronchial obstruction, which is manifested by an attack of suffocation, the appearance of wheezing (wheezing), coughing and / or difficulty breathing.

slide 3

The prevalence of asthma in Europe has doubled since the early 1980s In Ukraine, the prevalence of asthma among children has increased 1.6 times over the past decade regions suffer from BA much more often

slide 4

TYPES OF BRONCHIAL OBSTRUCTION:

Acute - due to spasm of the smooth muscles of the bronchi Subacute - due to edema of the bronchial mucosa Chronic - blockage of small and medium bronchi with a viscous secret Irreversible - due to the development of sclerotic changes in the bronchial wall with a long and severe course of the disease

slide 5

Predisposing factors:

Atopy - a hereditary predisposition to allergic reactions Bronchial hyperreactivity - an increased response of the bronchial tree to specific and nonspecific stimuli Hyperproduction of immunoglobulin E

slide 6

Sensitization factors:

Household: house and library dust, waste products of house dust mites, cockroaches, dry food for fish, feather pillows Non-pathogenic fungi (molds, yeasts) Epidermal allergens (cats, dogs) Plant allergens (pollen of trees, weeds, flowers) prematurity due to the immaturity of the lung tissue and the immune system

Slide 7

Resolving factors (triggers):

Pollutants - compounds of sulfur, nitrogen, nickel, CO - the result of the work of factories, exhaust gases of cars Smoking - active and passive SARS Food Household, vegetable and other allergens Physical activity Stress Meteorological factors

Slide 8

Ways to activate the immune response:

Allergen Mast cell Inflammatory mediators Allergen T-helper of the 2nd order Eosinophils, basophils, mast cells, etc. Inflammatory mediators Allergen T-helper of the 2nd order B-lymphocyte IgE Mast cell Types I, III and IV of allergic reactions are involved in the development of AD

Slide 9

Classification of asthma in children by severity

Mild - attacks no more than 1 time per month, mild, stop spontaneously or with a single use of bronchodilators, there are no symptoms in the period of remission. PSV and FEV1 more than 80% of the norm, daily fluctuations are not more than 20%. Moderately severe - attacks 3-4 times a month, with impaired function of external respiration, are stopped by bronchodilators or parenteral corticosteroids, remission is incomplete. PSV and FEV1 60 - 80% of the norm, daily fluctuations 20 - 30%. Severe - attacks several times a week or daily, severe, are stopped by bronchodilators and corticosteroids parenterally in a hospital, incomplete remission (respiratory failure of varying degrees. PSV and FEV1 less than 60% of the norm, daily fluctuations more than 30%.

Slide 10

Treatment of asthma in the acute period:

Termination of contact with the allergen Oxygen therapy Inhaled B2-agonists (salbutamol (Ventolin), terbutaline (Berotek)) or combined B2-agonists + M-anticholinergics (berodual, combivent) If 3 inhalations of B2-agonists within an hour are ineffective - intravenous theophylline and systemic glucocorticosteroids

slide 11

Basic therapy for AD:

Hypoallergenic diet, regimen measures Allergen-specific immunotherapy Cromones: sodium cromoglycate (Intal), sodium nedocromil (Tyled) Inhaled glucocorticosteroids: flunisolide (Ingacort), belomethasone dipropionate (Becotide, beclozone, beclocort, aldecine), budesonide (Pulmicort), fluticasone (Flixotide) ) Long-acting B2-agonists: salmeterol (serevent), formoterol (foradil) Antileukotriene drugs: montelukast, zafirlukast

View all slides

slide 1

slide 2

slide 3

slide 4

slide 5

slide 6

Slide 7

Slide 8

Slide 9

Slide 10

slide 11

The presentation on the topic "Bronchial asthma in children" can be downloaded absolutely free of charge on our website. Project subject: Medicine. Colorful slides and illustrations will help you keep your classmates or audience interested. To view the content, use the player, or if you want to download the report, click on the appropriate text under the player. The presentation contains 11 slide(s).

Presentation slides

slide 1

slide 2

Bronchial asthma -

slide 3

slide 4

TYPES OF BRONCHIAL OBSTRUCTION:

slide 5

Predisposing factors:

slide 6

Sensitization factors:

Slide 7

Resolving factors (triggers):

Slide 8

Ways to activate the immune response:

Slide 9

Classification of asthma in children by severity

Slide 10

Treatment of asthma in the acute period:

Try to involve the audience in the story, set up interaction with the audience using leading questions, the game part, do not be afraid to joke and smile sincerely (where appropriate).
Try to explain the slide in your own words, add additional interesting facts, you don’t just need to read the information from the slides, the audience can read it themselves.
No need to overload your project slides with text blocks, more illustrations and a minimum of text will better convey information and attract attention. Only the key information should be on the slide, the rest is better to tell the audience orally.
The text must be well readable, otherwise the audience will not be able to see the information provided, will be greatly distracted from the story, trying to make out at least something, or completely lose all interest. To do this, you need to choose the right font, taking into account where and how the presentation will be broadcast, and also choose the right combination of background and text.
It is important to rehearse your report, think over how you will greet the audience, what you will say first, how you will finish the presentation. All comes with experience.
Choose the right outfit, because. The speaker's clothing also plays a big role in the perception of his speech.
Try to speak confidently, fluently and coherently.
Try to enjoy the performance so you can be more relaxed and less anxious.